Claims

1. A crystalline form of *N*-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1*R*,2*S*)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide, characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 Å, comprising at least one crystalline peak with a 2-Theta value (in degrees) of 21.0, 28.8 and/or 29.1.

2. A form as claimed in Claim 1 characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 Å, comprising at least 2 crystalline peaks with a 2-Theta value (in degrees) of 21.0, 28.8 and/or 29.1.

3. A form as claimed in Claim 1 characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 Å, comprising at least 3 crystalline peaks with a 2-Theta value (in degrees) of 21.0, 28.8 and/or 29.1.

4. A form as claimed in any one of claims 1 to 3 characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 Å, comprising a further crystalline peak with a 2-Theta value (in degrees) selected from 12.9 and 18.0.

5. A form as claimed in Claim 1 characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 Å, comprising crystalline peaks with a 2-Theta value (in degrees) of 12.9, 13.1, 18.0, 21.0, 22.5, 25.1, 25.3, 28.8, 29.1 and 30.4.

6. A crystalline form of Compound I, which has a melting point (onset) of 152.7°C.

7. A form as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

8. A pharmaceutical formulation including a form as claimed in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

9. A form as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

10. The use of a form as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

11. A combination product comprising:

(I) (a) a form as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof; and

(b) one or more active ingredient that is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial, or a pharmaceutically-acceptable salt thereof;

(II) a pharmaceutical formulation including a form as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof; an active ingredient that is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial, or a pharmaceutically-acceptable salt thereof; and a pharmaceutically-acceptable adjuvant, diluent or carrier; and/or

(III) a kit of parts comprising components:

(A) a pharmaceutical formulation including a form as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and

(B) a pharmaceutical formulation including an active ingredient that is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,

which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.

Claims

1. A crystalline form of *N*-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1*R*,2*S*)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide, characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 Å, comprising crystalline peaks with a 2-Theta value in degrees of 12.9, 13.1, 18.0, 21.0, 22.5, 25.1, 25.3, 28.8, 29.1 and 30.4.

2. A crystalline form of Compound I, which has a onset melting point of 152.7°C.

3. A crystalline form as defined in any one of Claims 1 to 2, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

4. A pharmaceutical formulation including a crystalline form as claimed in any one of Claims 1 to 2, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant.

5. A crystalline form as defined in any one of Claims 1 to 2, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

6. The use of a crystalline form as defined in any one of Claims 1 to 2, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.